Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransport...

💡 Takeaway: “SGLT2 inhibitors = renal rescue in diabetes!”

🍪 www.nejm.org/doi/full/10....

#DiabetesAndCKD #SGLT2Inhibitors #NephrologyProgress